Which biosimilar has been shown to last longer in the eye compared to Afibercept?

The choice indicating that Brolucizumab lasts longer in the eye compared to Aflibercept is based on clinical studies and pharmacokinetic data. Brolucizumab is designed with a unique molecular structure that allows for a higher binding affinity to VEGF (vascular endothelial growth factor) and extended duration of action, which means that it can remain effective in the eye for a longer period compared to traditional therapies like Aflibercept.

This extended duration is particularly significant in the treatment of conditions associated with choroidal neovascularization (CNV), such as age-related macular degeneration (AMD). Longer-lasting medications can reduce the frequency of injections, potentially improving patient compliance and outcomes.

The other options, Ranibizumab and Bevacizumab, do not offer this same duration in the eye when compared to Aflibercept, mainly due to their different molecular sizes and binding characteristics, which affect how long they remain effective within ocular tissues. Aflibercept, while effective, typically requires more frequent dosing than Brolucizumab, consequently leading to the latter being the more favorable choice for prolonged effect.